DNA damage-inducing therapies are of tremendous value for cancer treatment and function
by the direct or indirect formation of DNA lesions and subsequent inhibition of cellular …

Purpose Fibroblast activation protein (FAP) is a membrane-bound protease that has limited
expression in normal adult tissues but is highly expressed in the tumor microenvironment of …

Targeted radionuclide therapy (TRT) uses radiopharmaceuticals to specifically irradiate
tumor cells while sparing healthy tissue. Response to this treatment highly depends on the …

With an increasing variety of radiopharmaceuticals for diagnostic or therapeutic nuclear
medicine as valuable diagnostic or treatment option, radiobiology plays an important role in …

Intravascular brachytherapy requires advances in radio‐embolization technologies that
combine brilliant radiostability efficacy with a facile and green synthesis route. A hybrid …

The overexpression of fibroblast activation protein-α (FAP) in solid cancers relative to levels
in normal tissues has led to its recognition as a target for delivering agents directly to tumors …

Radionuclide Therapy (RNT) with 177Lu-DOTATATE targeting somatostatin receptors
(SSTRs) in neuroendocrine tumours (NET) has been successfully used in routine clinical …

DNA is an organic molecule that is highly vulnerable to chemical alterations and breaks
caused by both internal and external factors. Cells possess complex and advanced …

Tumour heterogeneity is a common phenomenon in neuroendocrine neoplasms (NENs)
and a significant cause of treatment failure and disease progression. Genetic and epigenetic …

Rationale: An effective absorbed dose response relationship is yet to be established for
Lutetium-177 based radionuclide therapies such as 177 Lu-DOTATATE and 177 Lu-PSMA …